The federal Food and Drug Administration said Friday it will grant some patients early access to Revolution Medicines' experimental pancreatic cancer drug daraxonrasib.The drug — which former U.S. Sen. Ben Sasse, R-Nebraska, is being treated with for his stage 4 pancreatic cancers — hasn’t been approved by the FDA. But the FDA told the Redwood City, California, manufacturer it can begin an "expanded access treatment protocol" for some patients who previously have been treated for pancreatic canc...